In October, we added 110 citations in DIDB, including 47 in vitro (with 16 articles published in October 2023) and 63 in vivo articles (with 38 articles published in October 2023).
4 recently approved NDAs/BLAs were also added: elranatamab (ELREXFIO), momelotinib (OJJAARA), pozelimab (VEOPOZ), sotagliflozin (INPEFA).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.